Linkedin-in Twitter Facebook-f Instagram Youtube Envelope
GlycoNet and partners invest $7.7 million in Canadian health innovation
This investment will support state-of-the-art health research for Canada’s leading diseases, including cancer, diabetes, dementia, muscular dystrophy and universal donor blood.
Molecules with anti-inflammatory, restorative properties could be key to tackling neurodegenerative disease
GlycoNet researchers are studying a group of molecules that could provide insight into treating and monitoring neurodegenerative diseases.
GlycoNet researcher receives Scientific Achievement and Innovation Award
Dr. Ratmir Derda’s achievements were recently recognized with an award at BioAlberta’s 2021 Awards Gala.
Trainee at GlycoNet: Amaani Patel
Linkedin-in Twitter Facebook-f Instagram Youtube Envelope About About GlycoNet People Administration Corporate Policies Governance Board of Directors Executive Committee Finance & Audit Committee Nominating Committee Research Management Committee Scientific Advisory Board Commercialization & Legacy Committee Equity, Diversity and Inclusion Committee Training Committee Partners Become a Member Research Research Themes Technology Highlights Introduction to Glycomics Call […]
GlycoNet investigator presents game-changing glycomics research to the Parliamentary Health Research Caucus
Dr. Lori Burrows shared how glycomics research is being used to develop a more effective vaccine against turberculosis.
New research reveals clues to how antibodies get fine-tuned to fight infection
Scientists discover a cellular mechanism that may yield insights into improving vaccines and better understanding cancer and autoimmune diseases.
New educational resources bolster vaccine confidence, information literacy
GlycoNet received a NSERC PromoScience grant and partnered with the Centre for Mathematics, Science and Technology Education to develop resources that educators can use to teach the science behind vaccines and engage students in critical thinking.
New treatment could reduce tissue damage in Duchenne muscular dystrophy patients by as much as 50 per cent
A carbohydrate-derived drug shows promise as a treatment to slow progression of the most common form of muscular dystrophy.
Trainee at GlycoNet: F. Ifthiha Mohideen
Linkedin-in Twitter Facebook-f Instagram Youtube Envelope About About GlycoNet People Administration Corporate Policies Governance Board of Directors Executive Committee Finance & Audit Committee Nominating Committee Research Management Committee Scientific Advisory Board Commercialization & Legacy Committee Equity, Diversity and Inclusion Committee Training Committee Partners Become a Member Research Research Themes Technology Highlights Introduction to Glycomics Call […]
English 
French